Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026)

Amylyx Pharmaceuticals has reported Income from Continuing Operations for 6 years, with the latest figure at -$43.4 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 4.65% year-over-year to -$43.4 million in Q2 2026; TTM through Jun 2026 was -$121.5 million, a 2.42% increase from a year earlier, with the FY2025 full-year figure at -$114.3 million, up 52.11% from the prior year.
• Income from Continuing Operations was -$43.4 million for Q2 2026 at Amylyx Pharmaceuticals, down from -$41.2 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $25.5 million in Q4 2024, with the low at -$118.8 million in Q1 2024.
• Average Income from Continuing Operations over 5 years is -$32.7 million, with a median of -$41.3 million recorded in 2025.
• The largest YoY upside for Income from Continuing Operations was 466.01% in 2024 against a maximum downside of 7652.0% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$43.8 million in 2022, then surged by 110.29% to $4.5 million in 2023, then soared by 466.01% to $25.5 million in 2024, then plunged by 110.07% to -$2.6 million in 2025, then sank by 1588.21% to -$43.4 million in 2026.
• The last three Income from Continuing Operations figures came in at -$43.4 million (Q2 2026), -$41.2 million (Q1 2026), and -$2.6 million (Q4 2025), per Business Quant data.